TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01371201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 37.5 mg per day
Study: NCT00185172
Drug: olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
Study: NCT03217409
Drug: Rosuvastatin+Ezetimibe
Normalized name: ezetimibe / rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5mg+Ezetimibe 10mg
Study: NCT03217409
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5Mg Tablet
Study: NCT00486044
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet each night for one month, then 80 mg for 8 months
Study: NCT00486044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablet each night for 9 months
Study: NCT02737722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02870543
Drug: Phytolacca decandra
Normalized name: Phytolacca Decandra 6X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of bruxism
Study: NCT02870543
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of bruxism
Study: NCT02870543
Drug: Phyt.decandra + Melissa offic.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of bruxism
Study: NCT02171455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00075231
Drug: Combivir® (lamivudine, zidovudine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00075231
Drug: Sustiva® (efavirenz)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01919710
Drug: rHSA/GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: for treatment of neutropenia
Study: NCT00447759
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-400mg daily in divided doses
Study: NCT00447759
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: prescribed medication taken orally
Study: NCT02765165
Drug: USL311
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once weekly in a 21-day cycle
Study: NCT02765165
Drug: USL311
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in a 21-day cycle
Study: NCT02765165
Drug: USL311
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in a 42-day cycle
Study: NCT00505921
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
Study: NCT01493648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (lactose 100 mg) for 3 months.
Study: NCT00505921
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
Study: NCT00772837
Drug: Omeprazole + Clarithromycin + Amoxycillin
Normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
Study: NCT00079742
Drug: Nutropin AQ [somatropin (DNA origin) injection]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04579965
Drug: medical treatment of isthmocele
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison between different drugs
Study: NCT00141609
Drug: Slow Sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00025402
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04342169
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be taken on the same schedule as HCQ.
Study: NCT01349725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; matching placebo
Study: NCT02456896
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
Study: NCT00157053
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02860923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00660374
Drug: EX1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-treat-to-target dose titration scheme, injection s.c.
Study: NCT03937687
Drug: Caffeine+TeaCrine+Dynamine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination of caffeine, TeaCrine, and Dynamine
Study: NCT03937687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03937687
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine
Study: NCT00991276
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules; 0 mg once-per-day; 4 weeks of treatment
Study: NCT03813056
Drug: Optive, Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: artificial tears (placebo)
Study: NCT05163756
Drug: DW1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: q.d. PO, DW1903 + Placebo of DW1903-R1
Study: NCT00287339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule BID for 12 weeks
Study: NCT02774252
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
Study: NCT04598204
Drug: Treatment with oral rapmycin
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
Study: NCT00544362
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02240693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01386281
Drug: E2 transdermal (Julina, BAY86-5435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
Study: NCT01211522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
Study: NCT02411643
Drug: topical calcipotriene 0.005% ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affected area will be treated twice daily for 3 months
Study: NCT03282929
Drug: Part 2 group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
Study: NCT03393520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT00630344
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00249483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00657774
Drug: FlutiForm 250/10 ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
Study: NCT00657774
Drug: FlutiForm 100/10 ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
Study: NCT00657774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
Study: NCT01743651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
Study: NCT01579149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous (SC) dose of placebo
Study: NCT02742051
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant chemotherapy
Study: NCT02742051
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant chemotherapy
Study: NCT03124108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two coated tablets daily for 12 weeks
Study: NCT01570205
Drug: XG-102
Normalized name: Ninjacof XG
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous infusion
Study: NCT01839253
Drug: ACE inhibitor(Enapril)
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02224937
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02224937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01769482
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03432572
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active placebo not known to cause urine discoloration
Study: NCT00288236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02370043
Drug: KQ-791
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally while fasting, in up to 3 periods
Study: NCT02370043
Drug: KQ-791 (after meal)
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of KQ-791 in capsules, after a meal, in 1 period
Study: NCT02370043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, administered orally, in 1 period
Study: NCT02035124
Drug: BKM 120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04723186
Drug: MT1002 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
Study: NCT02105350
Drug: MEK 162
Normalized name: Mitogen-activated protein kinase (MEK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03480971
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
Study: NCT03168438
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
Study: NCT04427501
Drug: LY3819253
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00769418
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days.
Study: NCT04427501
Drug: LY3853113
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00806728
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
Study: NCT00806728
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
Study: NCT01359943
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AIN457 i.v. and to AIN457 s.c..
Study: NCT04427501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01898039
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
Study: NCT03124082
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous infusion intraop
Study: NCT04530344
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT00172107
Drug: ALX1-11 50 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
Study: NCT00172107
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo powder for subcutaneous injection
Study: NCT00172107
Drug: ALX1-11 75mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84)75 mcg for subcutaneous injection
Study: NCT00172107
Drug: ALX1-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
Study: NCT00026208
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 650 mg/m², on week 1 and 5
Study: NCT00026208
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m², on week 1, 3, 5, 7
Study: NCT00352183
Drug: Fenofibrate/Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fenofibrate and Simvastatin 40mg
Study: NCT00352183
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg
Study: NCT00546507
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01553851
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
Study: NCT00205166
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 400 mg po
Study: NCT00205166
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 200 mg po
Study: NCT04338529
Drug: Binosto 70Mg Effervescent Tablet
Normalized name: Binosto 70mg Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: As discussed in group descriptions
Study: NCT01723774
Drug: PD0332991
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02939183
Drug: Immediate Release (IR) Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) Formulation
Study: NCT02939183
Drug: Gastro-Retentive (GR) Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-Retentive (GR) Formulation
Study: NCT03416179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Study: NCT03416179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Study: NCT00484510
Drug: Ascorbic acid (Vitamin C)
Normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
Study: NCT01711125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 matched tabs/day
Study: NCT00484510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
Study: NCT02749331
Drug: AdVince
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus solution for infusion in intrahepatic artery
Study: NCT01299584
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT01465815
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01364220
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20mg tablet, once daily, for 14 days
Study: NCT02682121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT02424695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03057418
Drug: Aurixim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
Study: NCT00300729
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Study: NCT00300729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Study: NCT00568503
Drug: QAX028
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06108921
Drug: Salt Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
Study: NCT04423731
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.
Study: NCT04083183
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01573143
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
Study: NCT01573143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
Study: NCT02309359
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stable background dose of commercially available methotrexate (not provided by the Sponsor).
Study: NCT04137900
Drug: TAB004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection
Study: NCT04010305
Drug: Placebo film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo film for BXCL501
Study: NCT00499629
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule similar to active drug
Study: NCT01242787
Drug: LB80380
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)